Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 16/20 | 0.42 |
| ▸ | MMP2 | P08253 | 1/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3318601 | 0.86 | KIF11 (0.48) | KIF11MMP2 | |
| SCHEMBL1899105 | 0.85 | KIF11 (0.44) | KIF11PTGS1CYP1A2CYP2D6 | |
| SCHEMBL6072849 | 0.84 | KIF11 (0.55) | KIF11 | |
| SCHEMBL7486608 | 0.83 | KIF11 (0.42) | KIF11CYP1A2CYP2D6 | |
| SCHEMBL7486605 | 0.83 | KIF11 (0.42) | KIF11CYP1A2CYP2D6DNMT1 | |
| SCHEMBL14343479 | 0.82 | KIF11 (0.49) | KIF11DNMT1 | |
| SCHEMBL20553873 | 0.82 | KIF11 (0.41) | KIF11CYP1A2CYP2D6DNMT1 | |
| SCHEMBL8636658 | 0.81 | MMP2 (0.38) | KIF11MMP2CYP1A2 | |
| SCHEMBL6745551 | 0.80 | KMT2A (0.44) | KIF11CYP1A2CYP2D6 | |
| SCHEMBL9042463 | 0.79 | KMT2A (0.38) | KIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2050 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260116861-A1 | ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2026-04-30 | — | — | US | claimed |
| US-12522572-B2 | Isoxazole hydroxamic acids as histone deacetylase 6 inhibitors | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2026-01-13 | — | — | US | claimed |
| EP-4590346-A1 | FIBROBLAST ACTIVATION PROTEIN (FAP) INHIBITORS, FAP CONJUGATES, AND DIAGNOSTIC AND THERAPEUTIC USES THEREOF | Nuclidium AG (CH) | 2025-07-30 | — | — | EP | claimed |
| EP-4086250-B1 | MULTIFUNCTIONAL INHIBITORS OF MEK/PI3K AND MTOR/MEK/PI3K BIOLOGICAL PATHWAYS AND THERAPEUTIC METHODS USING THE SAME | UNIV MICHIGAN REGENTS (US) | 2024-12-11 | — | — | EP | claimed |
| US-20240343697-A1 | ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2024-10-17 | — | — | US | claimed |
| WO-2024064968-A1 | FIBROBLAST ACTIVATION PROTEIN (FAP) INHIBITORS, FAP CONJUGATES, AND DIAGNOSTIC AND THERAPEUTIC USES THEREOF | NUCLIDIUM AG (CH) | 2024-03-28 | — | — | WO | claimed |
| CN-116715728-A | Method for preparing supermolecule spiral assembly monocrystal by using R-configuration cyclic pentapeptide | 深圳湾实验室坪山生物医药研发转化中心 | 2023-09-08 | — | — | CN | claimed |
| EP-2805945-B1 | Amide substituted indazoles as poly(ADP-ribose)polymerase (PARP) inhibitors | MSD ITALIA SRL (IT) | 2019-04-03 | — | — | EP | claimed |
| US-20170360950-A1 | DRUG DELIVERY CONJUGATES CONTAINING UNNATURAL AMINO ACIDS AND METHODS FOR USING | ENDOCYTE INC (US) | 2017-12-21 | — | — | US | claimed |
| US-9707248-B2 | Use of thiopyrimidinecarboxamide for treating cancer | SYNTRIX BIOSYSTEMS INC. (US) | 2017-07-18 | — | — | US | claimed |
| US-20040132736-A1 | 17 Beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases | SCHERING CORPORATION | 2004-07-08 | — | — | US | claimed |
| EP-1423381-A1 | 17BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 3 INHIBITORS FOR THE TREATMENT OF ANDROGEN DEPENDENT DISEASES | Schering Corporation (US) | 2004-06-02 | — | — | EP | claimed |
| WO-2004030627-A2 | SYNERGISTIC METHODS AND COMPOSITIONS FOR TREATING CANCER | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-04-15 | — | — | WO | claimed |
| US-20040072760-A1 | Synergistic methods and compositions for treating cancer | BRISTOL-MYERS SQUIBB COMPANY | 2004-04-15 | — | — | US | claimed |
| US-20030232837-A1 | 17-Beta hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases | SCHERING CORPORATION | 2003-12-18 | — | — | US | claimed |
| EP-1313725-A1 | TRICYCLIC ANTITUMOR COMPOUNDS BEING FARNESYL PROTEIN TRANSFERASE INHIBITORS | SCHERING CORPORATION (US) | 2003-05-28 | — | — | EP | claimed |
| WO-2003033487-A1 | PIPERIDINE- AND PIPERAZINEACETAMINES AS 17BETA HYDROXYSTEROID DEHYDROGENASE TYPE 3 INHIBITORS FOR THE TREATMENT OF ANDROGEN DEPENDENT DISEASES | SCHERING CORPORATION (US) | 2003-04-24 | — | — | WO | claimed |
| WO-2003022835-A1 | 17BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 3 INHIBITORS FOR THE TREATMENT OF ANDROGEN DEPENDENT DISEASES | SCHERING CORPORATION (US) | 2003-03-20 | — | — | WO | claimed |
| US-20020198216-A1 | Novel farnesyl protein transferase inhibitors as antitumor agents | PHARMACOPEIA DRUG DISCOVERY | 2002-12-26 | — | — | US | claimed |
| WO-2002018368-A1 | TRICYCLIC ANTITUMOR COMPOUNDS BEING FARNESYL PROTEIN TRANSFERASE INHIBITORS | SCHERING CORPORATION (US) | 2002-03-07 | — | — | WO | claimed |